T1	Participants 698 783	A total of 22 rigorously selected cases were enrolled, 13 of whom completed the trial
T2	Participants 785 895	They were 16-42 years of age and had newly acquired attention deficits persisting for 6-34 months post-injury.
T3	Participants 405 604	It was the first study of lisdexamfetamine dimesylate with this population and, in fact, was the first controlled trial in this area examining a stimulant medication option other than methylphenidate
T4	Participants 0 112	Traumatic brain injury-related attention deficits: treatment outcomes with lisdexamfetamine dimesylate (Vyvanse)
